TG Therapeutics, Inc. (TGTX) AI Stock Analysis

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing treatments for B-cell malignancies and autoimmune diseases. Its pipeline includes Ublituximab, a glycoengineered monoclonal antibody investigated for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing multiple sclerosis. It also develops Umbralisib, an oral inhibitor targeting PI3K-delta and CK1-epsilon for lymphoma and CLL, and Cosibelimab, a human monoclonal antibody targeting PD-L1. Additional product candidates include TG-1701, a selective BTK inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19, alongside licensed preclinical programs targeting BET, IRAK-4, and GITR.

Annual revenue rose from $2.8M in FY2022 to $233.7M in FY2023, $329.0M in FY2024, and $616.3M in FY2025, representing an 87.3% increase in FY2025. Net income reached $447.2M in FY2025 compared to $23.4M in FY2024, resulting in a net margin of 72.6% and EPS of $0.50. Across the trailing twelve months ended June 30, 2026, revenue totaled $799.5M with an operating margin of 9.0% and a profit margin of 55.2%. In the latest quarter ended June 30, 2026, revenue increased 70.3% year-over-year, while quarterly earnings fell 70.6%.

As of June 30, 2026, TG Therapeutics held $552.2M in cash and short-term investments against total debt of $754.4M, leaving net debt at $202.2M. The company reported a current ratio of 4.27 and a debt-to-equity ratio of 1.25 on shareholders' equity of $604.1M. In FY2025, operating cash flow stood at -$24.8M and free cash flow was -$25.0M. Capital expenditures were $214,000, and the company spent $91.2M on share buybacks.

TG Therapeutics has a market capitalization of $8.26B and an enterprise value of $8.75B. Its trailing P/E ratio is 19.6x, below the 24.6x median of its US-listed Healthcare peers. In contrast, its forward P/E of 25.9x and EV/EBITDA of 62.8x trade at a premium to peer medians of 17.3x and 12.0x, respectively. The stock's price-to-sales ratio stands at 10.3x versus the peer median of 4.1x. Over the past year, the stock returned 54.8% compared to 16.8% for the S&P 500 (SPY), while its 5-year return of 62.0% trailed the index's 83.0%.

Wall Street coverage consists of 6 Strong Buy, 1 Buy, 0 Hold, and 1 Sell ratings. The mean price target is $69.71, which is 29.2% above the last closing price of $53.97. For FY2026 ending December 31, 2026, consensus estimates project revenue of $960.3M and EPS of $0.95, reflecting a 65.7% decline in earnings. The company delivered 0 EPS beats over the last 4 quarters, with its next earnings release scheduled for November 2, 2026.

This page is an AI-written research summary of TG Therapeutics, Inc. (TGTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TGTX income statement, TGTX balance sheet, TGTX key metrics, TGTX analyst forecast, TGTX chart. See the TGTX stock overview for the latest quote and news.